GLP-1 Clinical Relevance #42Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical CommentaryObservational StudyObesity TreatmentGLP-1 Receptor AgonistEndocrinologyAdults with ObesityAdverse Event ReportingAppetite RegulationAI Health ResearchSocial Media SurveillanceUnderreported...
Canada’s Cannabis Safety Surveillance System: What Six Years of Adverse Reaction Reports Reveal
Overall, individuals reporting an adverse reaction to a cannabis product (n=698) were 56.0 ± 20.0 years of age. 45.4% of reporting individuals were female, and 67.5% of individuals self-reported using cannabis for medical purposes… Most cases were reported as serious (62.3%), citing ‘other medically important condition’ as the primary reason for seriousness (58.6%), and 68.8% of all cases involved cannabis extracts.
GLP-1 Receptor Agonist Side Effects: AI Uncovers New Data
GLP-1 Clinical Relevance #44Contextual Information Background context; limited direct clinical applicability. ⚕ GLP-1 News | CED Clinic Clinical NewsObservational StudyGLP-1 Side EffectsSemaglutideTirzepatideEndocrinologyAdults with ObesityAdverse Event DetectionArtificial IntelligenceSocial Media AnalysisPatient Reported OutcomesPharmacovigilance Why...